Intralesional pentoxifylline as an adjuvant treatment for perioral post-burn hypertrophic scars.
Pentoxifylline (PTF), a methylxanthine derivative, has therapeutic use as an antifibrotic agent. In vitro, PTF inhibits the production of collagen and reduces the proliferation of fibroblasts in hypertrophic scars. This study aimed to evaluate changes in the elasticity of hypertrophic scars in the peribuccal area in burned patients, who presented with mouth-opening limitation. Eighteen patients were divided into two groups. The case group (n=10) was treated with PTF 1 mg ml(-1), while in the control group (n=8) no treatment was performed. Measurements of mouth opening (lip-to-lip and tooth-to-tooth distances in mm) were taken, before and after five therapeutic sessions with pentoxifylline with weekly intervals. The variations of these measures (Delta%) were calculated and submitted to statistical analyses. There was a significant improvement in the opening of the mouth, in vermilion distance (V=3.20 mm) as much as the dental distance (DD=4.19 mm) in the treated group, than in the control group. It was noted that pentoxifylline increases the elasticity of hypertrophic scars in the perioral area.
Isaac
Cesar
C
Faculty of Medicine, Cell Culture and Wound Healing Research Laboratory, Division of Plastic Surgery, University of São Paulo, Avenida Doutor Arnaldo 455 Sala 1360, São Paulo, Brazil. cesaris@plastica.fm.usp.br
Carvalho
Viviane Fernandes
VF
Paggiaro
André Oliveira
AO
de Maio
Mauricio
M
Ferreira
Marcus Castro
MC
D000293:Adolescent; D000328:Adult; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D002056:Burns / Q000150:complications*; D002648:Child; D017439:Cicatrix, Hypertrophic / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000293:injuries / Q000473:pathology; D017060:Patient Satisfaction; D010431:Pentoxifylline / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D055815:Young Adult
D000933:Antifibrinolytic Agents; D010726:Phosphodiesterase Inhibitors; D010431:Pentoxifylline